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Virus-specific CTL are an important factor in the control and elimination ofviral
infections (1-10). These cells recognize viral antigen in association with H-2 class
I, or in some instances, class II molecules (1, 11, 12). In recent years, there has been
considerable progress in documenting the biological significance of CTL and in
defining and mapping the antigenic epitopes recognized by such cells (1-16). How-
ever, relatively little is known about the life span of virus-specific CTL.
We and others (10, 17, 18) have shown that a chronic lymphocytic choriomenin-
gitis virus (LCMV) I infection can be eliminated by adoptive transfer of CD8+ T
cells from LCMVimmune mice. However, it is not known for how long the trans-
ferred donor CTL retain biological activity and persist in the cured carrier host.
To address this question, we have used congenic mice (Thy-1.1 and Thy-1.2) in the
adoptive transfer experiments, making it possible to distinguish between activity
due to immune donor T cells (Thy-1.1) and carrier host T cells (Thy-1.2). In this
study we show that the transferred CTL persist indefinitely in the cured carrier mice.
These donor CD8+ T cells can be recovered as late as 9 mo post-transfer and still
exhibit biological activity against LCMV both in vitro and in vivo. They kill LCMV
infected cells in vitro, are capable of massive proliferation in vivo, and can control
an LCMV infection upon transfer into a second infected recipient. These results
suggest that virus-specific CTL have the potential to persist for the life span of the
host as memory T cells.
Materials and Methods
Mice.
￿
C57BL/6 (H-26; Thy-1.2) and B6.PLThy-la/cy (H-2n; Thy-1.1) mice were pur-
chased from The Jackson Laboratory, Bar Harbor, ME. These two strains of mice will be
referred to as B6.Thy-1.2 and B6.Thy-1.1, respectively. Both neonatally and congenitally in-
fected B6.Thy-1.2 mice were used. Neonatally infected carriers were made by injecting 104
plaque-forming units (PFU) of LCMV intracerebrally into mice within 24 h of birth. The
congenital carrier colony was derived from these neonatally infected mice and bred at UCLA,
Los Angeles, CA. LCMVimmune mice were made by injecting 6-12-wk-old B6.Thy-1.1 mice
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intraperitoneally with 105 PFU of LCMV . Spleen and lymph nodes (LN) were taken 30-90 d
post-infection and used as LCMVspecific immune cells.
Virus.
￿
The Armstrong CA 1371 strain of LCMV (Arm-7) and a variant derived from
this virus (Arm-13) were used in this study (6). Arm-7 was used for injecting the adult B6Thy-1.1
mice to make immune mice, whereas Arm-13 was used to establish the B6.Thy-1.2 LCMV
carrier colony. The An3739 strain of Pichinde virus was used in "Cr-release assays as a con-
trol for virus specificity of the effector cytotoxic T cells.
Antisera.
￿
The following mAbs were used in the study. The mAbs antiThy-1.2 (HO-13-4)
and anti-Lyt-2 .2 (Ad4[15]) were purchased in the form ofascites fluidfrom Cedarlane, Hornby,
Ontario, Canada. AntiThy-1.1 (Tn-26a) was obtained from Miles Laboratories, Inc., Naper-
ville, IL, as an ascites. All reagents were used at concentrations specified by suppliers. The
rat anti-mouse hybridoma (GK1 .5) that reacts with the CD4 antigen was obtained from the
American Type Culture Collection, Rockville, MD, and grown in our laboratory (19). The
GK1.5 antibody was partially purified from culture supernatants by precipitation with a 50 ,70
saturated solution of ammonium sulfate. The antibody concentration was determined by an
immunodiffusion test with rat IgG standards. The rat anti-mouse mAb RL172 .4 was kindly
provided by Michael Bevan, Scripps Clinic and Research Foundation, La Jolla, CA. This
antibody (IgM) also reacts with the CD4 surface molecule and is effective in in vitro
complement-mediated depletion of CD4* cells (20). To deplete Thy-1.1* cells in vivo, the
mAb 19E1 .2 was used. Hybridomas producing this antibody were obtained from Michael
Bevan, and grown in our laboratory at UCLA. To confirm the specificity of mAb 19EL2,
B6.Thy-1.1 and B6.Thy-1.2 mice were injected with 0.5 ml of supernatant from 19E1.2 hy-
bridoma cells every other day, for a total of five injections. This treatment had no effect in
B6.Thy-1.2 mice but depleted >90% of T cells from B6.Thy-1.1 mice. The specificities ofmAbs
AD4-15 (anti-Lyt-2), Tn-26a (antiThy-1 .1), and HO-13-4 (antiThy-1.2) were confirmed by
a functional assay. Spleen and LN cells of mice infected with LCMV 8 d previously were
treated with either complement (C') alone or with mAb plus C'. The lymphocytes were then
tested in a cytotoxicity assay. Treatment of cells with anti-Lyt-2 completely abrogated cyto-
toxic activity of lymphocytes from both B6.Thy-1.1 and B6.Thy-1.2 mice. AntiThy-1.1 treat-
ment eliminated CTL activity of lymphocytes derived from Thy-1 .1, but not Thy-1.2, mice.
AntiThy-1.2 depleted specific activity only when effector cells were from B6.Thy-1.2 mice.
Flow Cytometry.
￿
Donor and host CD4* and CD8* T cells present in the spleens and LNs
of cured carrier mice were quantitated by flow cytometry. Both the FITC-conjugated
anti-mouse Thy-1 .1 (Tn-26) and FITC-conjugated anti-mouse Thy-1.2 were obtained from
ICN ImmunoBiologicals, Lisle, IL. Phycoerythrin (PE)-conjugated anti-mouse CD4 mAb
(clone GK1.5), biotin-conjugated anti-mouse CD8 mAb (clone 53-6), and strepavidin-PE
were purchased from Becton Dickinson & Co., Mountain View, CA.
Cells (106 per group) were costained simultaneously with one of the FITC-conjugated anti-
Thy-1 mAbs and either PE-conjugated anti-CD4 or biotin-conjugated anti-mouse CD8 . The
cells were washed and strepavidin-PE was added to the groups stained for the CD8 antigen.
After a final wash, all cells were fixed in 1% buffered formalin phosphate and 104 cells were
analyzed on either an Epics V (Coulter Electronics Inc., Hialeah, FL) coupled to an Innova
90 argon laser (Coherent Inc., Palo Alto, CA), or in a FAGS II (Becton Dickinson & Co.) .
The gates were set to include lymphocytes and blast cells.
Virus Titrations.
￿
Infectious LCMVwas quantitated by plaque assay on Vero cell monolayers
as previously described (6) .
Immune Therapy ofPersistently Infected Mice.
￿
Adult B6.Thy-1.1 immune mice (infected 30-90d
earlier with LCMV) were used as donors of spleen and LN cells. After death, their spleen
and LNs were harvested and single cell suspensions were prepared in MEM supplemented
with antibiotics and L-glutamine. Erythrocytes were removed by one cycle of treatment with
0.83% NH4Cl solution. 2 x 101 spleen and LN cells were transferred intraperitoneally or
intravenously into 6-12 wk-old B6.Thy-1.2 LCMV carrier mice. These treated carrier mice
were then monitored for viralclearance. Various tissues were tested for the presence of infec-
tious virus by plaque assay and for viral antigen by immunofluorescence (18).
Detection ofLCMV-specific CTL in Carrier Mice (Thy-1.2) Receiving Adoptive Transfer of Immune
Thy-1.1 Cells.
￿
At various times after immune therapy the treated carrier mice were killedJAMIESON AND AHMED
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and their spleen and LN cells tested for the presence of LCMV-specific CTL after stimula-
tion with virus for 8 d in vivo (in irradiated mice). About 2-5 x 10' pooled spleen and LN
cells from treated carrier mice (Thy-1.1 - Thy-1 .2) were injected intravenously into normal
mice irradiated (650 rad) 1 or 2 d previously. Unless otherwise stated, these irradiated recip-
ient mice were B6Thy-1.2. At the time of cell transfer, irradiated recipients were challenged
intravenously with 105 PFU of LCMV Arm 7. 8 d later, the recipient mice were killed and
the spleen and axillary, inguinal, and cervical LNs were harvested and assayed for CTL ac-
tivity. The phenotype (Thy-1.1 or Thy-l.2) ofthe CTL was determined by complement-mediated
depletion using Thy-1.1- and Thy-1 .2-specific mAbs as described previously (21).
T Cell Depletion.
￿
To deplete donor T cells, spleen and LN cells from cured carrier mice
were treated in vitro with antiThy-1.1 (Tn-26) plus C' and transferred intravenously into ir-
radiated recipients for in vivo stimulation. The irradiated recipients were injected in-
traperitoneally with 0.5 ml of 19EL2 at the time of cell transfer and again on day +2 and
+3 to further deplete donor T cells in vivo. The depletion of host T cells was accomplished
in vitro with two rounds of antiThy-1.2 (HO-13-4) plus C: CD4' T cells were depleted in
vitro with two rounds of RL172.4 plus Cand the remaining spleen and LN cells were trans-
ferred intravenously into irradiated mice. CD4' cells were then further depleted by injecting
the irradiated recipients with 0.5 ml of GK1.5 at the time ofcell transfer and again on day 3 .
LCMV-specificCTLAssay.
￿
Single-cell suspensions of spleen and lymph nodes, free oferythro-
cytes, were prepared in complete RPMI medium supplemented with 10To heat-inactivated
FCS, antibiotics, and L-glutamine. The cells were then tested for cytotoxicity on uninfected,
LCMVinfected, or Pichinde virus-infected MC57 (H-2b) or BALB CL-7 (H-2d) fibroblasts.
MC57 cells were infected 48 h before use with the indicated virus at a multiplicity ofinfection
of 0.5 PFU/cell. BALB CL-7 cells were infected at a multiplicity of infection of 0.5 PFU
with the indicated virus 24 h before use. The target cellswere labeled with "Cr and the cy-
totoxicityassay was performed as previously described (6). Test duration was 6 h and samples
were run in triplicate. The percent specific
5 Cr release was calculated as follows: 100x
[(Sample release - spontaneous release [cpm])/(maximum - spontaneous release [cpm])] .
Results
Long-term Persistence ofAdoptively Transferred LCMV-specific CTL.
￿
The lifelong chronic
LCMV infection ofcongenitally infected carrier mice can be eliminated by adoptive
transfer of CD8+, MHC class I-restricted, virus-specific T cells derived from adult
immune mice (10, 17, 18, 22). To determine the life span of the donor T cell popula-
tion in the cured carrier host, we examined the time course during which donor-
derived T cells and donor cytotoxic T cell activity could be recovered. To allow us
to identify the donor T cells and to distinguish between their activity and the ac-
tivity ofthe host T cells, we used mice congenic at the Thy-1 locus in adoptive transfer
experiments. Immune cells from B6.Thy-1.1 (donor) mice were adoptively transferred
into B6.Thy-1 .2 carrier (host) mice. Viral clearance from treated carrier mice was
then monitored by determining the level ofinfectious virus in blood and several other
tissues. At various times post-transfer, mice with no detectable viremia were killed
and the presence ofLCMVspecific CTL activity was checked in their spleen and
LN cells. Freshly isolated lymphocytes from treated carrier mice did not exhibit CTL
activity and showed minimal or no killing ofvirally infected cells (data not shown).
However, an LCMV-specific CTL response was readily detectable when these lym-
phocytes were stimulated with virus for 8 d in irradiated recipient mice. This pro-
tocol of in vivo stimulation with virus was used in all experiments to monitor.the
presence of virus-specific CTL in treated carrier mice. The data from several such
experiments are summarized in Fig. 1 and details of one particular experiment are
shown in Table I. As demonstrated in Fig. 1, an LCMV-specific CTL response was1996
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FIGURE 1 .
￿
Persistence of donor-derived LCMVspecific CTL (Thy-1 .1) in carrier mice (Thy-
1.2). Spleen andLN cells were harvested from cured carriermice (Thy-1 .2) at the indicated times
after transfer of immune T cells (Thy-1 .1) and tested forCTL activity after in vivo stimulation
with virus as described in Materials and Methods . The phenotype (Thy-1 .1 or Thy-1.2) of the
CTL was determined by complement-mediated depletion usingThyl .l- andThy1.2-specific mAbs .
The data shown is percent specific killing of infected targets at an E/T ratio of 50 :1 .
easily detectable and most of the killingwas mediated by the donor Thy-1.1 T cells
present in cured carrier mice . Donor-derived CTL activity was present at all time
points checked and could be recovered as late as 274 d post-transfer. Although there
is some variation in the magnitude of the response, no decline in CTL activity was
observed at the later time points . Table I shows in detail recovery of donor Thy-1 .1
CTL activity from cured carrier mice 274 d post-transfer. Depletion of host Thy-
1 .2+T cells from the effector population had no effect on the magnitude of theCTL
response . In contrast, depletion of either donor Thy-1.1+ or CD8+T cells completely
abrogated LCMVspecific cytotoxicity, demonstrating that the effectors were CD8+
Tcells ofdonorThy-1.1 origin . These resultsshow that as late as 274d post-transfer,
donor Thy-1 .1 T cells are still present in the cured carrier host and retain CTL ac-
tivity against LCMV. TheCD8 + Thy-1.1' T cells wereMHC class I restricted (no
killing ofLCMVinfected H-2d cells) and virus specific as they did not lyse unin-
fected or Pichinde virus-infected H-2b targets (data not shown) .
Long-lived Donor TCells Retain In Vivo Antiviral Activity againstLCMV .
￿
In addition
to mediating in vitroCTL activity, these long-lived donorT cells are biologically
active in vivo and can eliminate virus from a second infected recipient . When Thy-
1 .1+ donorT cells isolated from cured carrier mice are transferred into irradiated
mice infected with LCMV, they can control the viral infection . The results of one
such experiment are shown in Table II . No detectable virus was found in mice that
received the Thy-1.1 T cells, in contrast to the high levels of infectious LCMV in
organs of irradiated mice receiving virus but no cells .
In Vivo Proliferation of Long-lived DonorCD8+ T Cells.
￿
The cured carrier spleens
and LNs were examined by flow cytometry for the relative percentages of donor
and host CD4' and CD8+ T cells both before and after in vivo stimulation with
LCMV. Single cell suspensions of pre- and post-stimulation lymphocytes were co-
stained forthe Thy-1 .1 or Thy-1.2 antigenand either theCD4or CD8 surfacemarkerJAMIESON AND AHMED
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TABLE I
Recovery ofDonor LCMV-speck Cytotoxic T Cells 274 d after Cell Transfer
CTL response (percent specific 51Cr
release from MC57 [H-26] targets)
Spleen and LN cells from cured carrier mice (274 d post-transfer) were stimulated with LCMV in vivo
in irradiated mice and CTL activity determined 8 d post-stimulation.
1 6-8-wk-old normal B6.Thy-1 .2 andB6.Thy-1 .1 mice were injected intravenously with 105 PFU of LCMV
8 d before testing for CTL activity as controls for specificity of the anti-Thy-1 .2 and anti-Thy-1 .1 mAbs.
(see Materials and Methods). Although the donor T cells represented only a minor
population ofthe freshly isolated resting lymphocytes from cured carrier mice, this
population underwent tremendous expansion when stimulated with LCMV The
results presented in Fig. 2 and Table III show that this expansion of donor T cells
occurred almost exclusively within the donor CD8+ subset . In experiment 1 (see
Fig. 2 and Table III), carrier mice that had received Thy-1.1+ Tcells 274 d earlier
were used. Whentheirpooled spleen and LN cells were analyzed by flow cytometry,
TABLE II
Donor (Thy-1.1) T Cells Recoveredfrom Cured Carriers
Can Eliminate Virus from a Second Infected Recipient
Types of cells
￿
Infectious virus 8 d post-transfer
transferred Serum Liver Spleen Lung
loglo PFU/ml
None
￿
3.6 t 0.34 4.7 t 0.34 4.6±0 .6 3.8±0.19
Thy-1 .1' T cells
from cured carriers
￿
<1 .6
￿
<1 .6
￿
<1.6
￿
<1 .6
Donor Thy-1 .1 T cells were obtained from cured carrier mice (61 d after cell
transfer) after complement-mediated depletion ofhost Thy-1 .2 Tcells. This en-
riched populationofdonor (Thy-1 .1) Tcells wastransferred into irradiated mice
infected with LCMV . Theamount of infectious virus in various tissues wasde-
termined 8 d later. LCMV-infected mice that received no cells served as con-
trols. Virus titers are the averages of two to six mice.
Group Treatment
LCMV infected
E/T ratio
5.5:1 16.6:1 50:1
Uninfected
E/T ratio
50:1
Cured carrier' C' 15 31 52 1
(Thy-1 .1-Thy-1 .2) Anti-Thy-1 .1 + C' 1 2 5 0
Anti-Thy-1 .2 + C' 12 29 51 1
Anti-Thy-1 .1 + C' + anti-Thy-1 .2 + C' 0 1 2 0
Anti-CD8 + C' 2 1 2 0
B6 .Thy-1 .11 C' 12 32 47 2
Anti-Thy-1 .1 + C' 1 4 12 1
Anti-Thy-1 .2 + C' 14 34 50 3
Anti-Thy-1 .1 + C' + anti-Thy-1 .2 + C' 0 1 6 2
Anti-CD8 + C' 0 1 3 0
B6.Thy-1 .21 C' 11 32 52 4
Anti-Thy-1 .1 + C' 11 29 47 2
Anti-Thy-1 .2 + C' 0 0 1 0
Anti-Thy-1 .1 + C' + anti-Thy-1 .2 + C' 0 0 0 0
Anti-CD8 + C' 0 5 10 01998
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2
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Proliferation
of donor Thy-1
.1
CD8'
T cells after stimulation with LCMV
.
Spleen
and LN cellswere obtained from cured
carrier
(Thy-1
.2)
mice 274 d after transfer of
LCMV
immune Thy-1
.1
T cells
.
Cells were
costained
for the Thy-1
.1
antigen (green) and
either
the CD4 or CD8 (red) surface marker
and
analyzed by flow cytometry
.
The "pre"
sample
is the freshly isolated resting lympho-
cytes
from cured carrier mice (274 d post-
transfer).
The "post" sample is the same cell
population
after 8d ofin vivo stimulation with
LCMV
in irradiated normal B6 Thy-1
.2
mice
.
Note
the expansion of the Thy-1
.1
CD8' T
cells.
The expansion is not seen ifthe cells are
transferred
into uninfected normal B6 Thy-
1.2
mice (data not shown)
.
the
donor Thy-1
.1
+ CD8+ T cells comprised only 3 % of the total population, but
after
stimulation with LCMV this minor population of T cells expanded within
8
d to comprise the majority (52 %) of the pooled spleen and LN cells
.
In this partic-
ular
experiment, there was a sevenfold increase in the total number of Thy-1
.1
+
CD8+
T cells based on the total number of cells initially transferred into irradiated
mice
and the number recovered 8 d later
.
This sevenfold increase is an underesti-
mate
of the actual expansion because not all post-stimulation cells were recovered
.
Only
the spleen and the axillary, cervical, and inguinal LNs were recovered from
each
irradiated recipient, and some donor T cells would have been left in the re-
maining
LNs and in the blood
.
The data from experiment 2 (Table III) show basi-
cally
the same pattern
;
the donor CD8+ T cells initially constitute a minor popula-
tion
but proliferate in vivo upon exposure to virus and become the major cell type
present.
The
expansion of CD8+ cells was not matched by the Thy-1
.1+
CD4+ T cell
subset.
Fig
.
2 and Table III (experiments 1 and 2) show that the Thy-1
.1+
CD4+
TABLE
III
In
Vivo Proliferation of Long-lived Donor CD8+ T Cells
"
Aliquots of pre- and post-stimulation (8 d after infection) spleen and LN cells were double stained with
labeled
mAbs for the indicated surface markers and analysed by flow cytometry as described in Materials
and
Methods
.
t
Cured carrier mice 274 d after transfer of donor T cells were used
.
S
These mice were from two groups of cured carriers 82 and 110 d post-cell transfer
.
Percent of
total spleen and LN
cells
from cured
carrier
mice
(Thy-1 .1-Thy-1 .2)"
Stimulation Donor Host
Exp. with
LCMV
Thy-1 .1'CD4+ Thy-1 .1'CD8' Thy-1 .2+CD4' Thy-1 .2'CD8+
11 -
(Pre)
4 .0 3 .0 19.0 16.0
+
(Post)
3 .0 52.0 11 .0 16.0
2S -
(Pre)
2 .1 2 .0 18.5 13 .9
+
(Post)
5 .5 28.2 14.6 25.8Group (percent CD4' T cells)
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Tcells donot exhibitany major expansion after stimulationwith LCMV . This subset
represented 4% (experiment 1) and 2.1% (experiment 2) of the cured carrier lym-
phocytes before stimulation and 3% (experiment 1) and 5.5% (experiment 2) 8 d
after stimulation with LCMV.
Effect of CD4+ T Cell Depletion on Donor CD8+ Proliferation, Generation ofa CTL Re-
sponse, and Viral Clearance. . To investigate the role ofCD4+ T cells in the induction
of anti-LCMV responses mediated by these long-lived donor CD8+ T cells, both
host and donor CD4+ cells were depleted before, and during, in vivo stimulation
ofthe cured carrier lymphocytes. As shown in Table IV, depletion ofCD4+ T cells
had no detectable effect on the proliferation of donor CD8+ T cells and minimal
to no effect on the generation ofLCMVspecific CTL responses and viral clearance.
Depletion of CD4' T cells was quite effective and there were <1% CD4+ T cells
in the CD4-depleted mice as determined by flow cytometry. Despite this reduction
in number ofCD4+ T cells, the average numbers oflymphocytes recovered per ir-
radiated recipient were equal for both the CD4-depleted and mock-treated groups
(data not shown). The equal proliferation, the potent CTL response, and effective
viral clearance by the CD8+ cells in the C134-depleted group demonstrates a min-
imal requirement for CD4+ T cells in the induction ofthe anti-LCMV activities
of these long-lived donor CD8+ T cells.
ImmunodominanceofDonor T Cells over Host-derivedLCMV-specific CTL Response.
￿
We
have previously reported that the cured carrier mice can make a host-derived (Thy-
1.2) LCMVspecific CTL response (21). In these earlierstudies, donor (Thy-1.1)T cells
TABLE IV
Donor CD8` T Cells Proliferate, Mediate an LCMV-specific CTL Response, and Control
Virus Infection Even After Depletion of CD4+ T Cells
Donor-derived LCMV-specific
CTL activity (percent
Proliferation of
￿
specific 5'Cr release at
￿
Control of LCMV
donor cells
￿
indicated E/T ratio)
￿
infection
Percent
￿
LCMV infected
￿
Uninfected
￿
(LCMV titer)
Thy-1 .1'CD8' cells 5 .5:1 16.6:1 50:1
￿
50:1
￿
Serum Lung Liver
logo PFU/ml
Mock (16.4)
￿
27 .4
￿
10.4
￿
33.8
￿
54.9
￿
0
￿
<1 .6
￿
<1 .6
￿
<1 .6
<1 .6 <1 .6 <1 .6
<1 .6 <1.6 <1 .6
<1 .6 <1 .6 <1 .6
CD4 depleted (<1 .0)
￿
29 .1
￿
7.8
￿
23.9
￿
50.5
￿
0
￿
<1 .6
￿
<1.6
￿
<1 .6
<1 .6 <1.6 <1 .6
<1 .6 <1 .6 <1 .6
<1 .6 <1.6 <1 .6
Spleen and LN cells from nine cured carrier mice (95 d post-transfer of Thy-1 .1' T cells) were pooled and
then divided into two groups of equal numbers of cells . To deplete CD4' T cells (CD4-depleted group),
cells were treated in vitro with two rounds of RL172.4 plus C' and transferred intravenously into infected
irradiated mice for in vivo stimulation with LCMV. Each irradiated recipient was injected intraperitoneally
with 0.5 mg of GK1 .5 at the time of cell transfer and again on day 3 to further deplete any remaining CD4'
T cells. In the mock group cells were treated twice in vitro with C' only before transfer into irradiated recipients.
Proliferation of CD8' T cells, LCMV-specific CTL response, and virus titers were determined 8 d post-
infection as described in Materials and Methods.2000
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7cell pope laticn
depleted before
stimulation D
None
Donor
Host
Donor
and
Host
Anti-LCMV CTL Response, %Specific SI Cr Release
￿
FIGURE 3.
￿
Depletion of im
ID
￿
20
￿
30
￿
40
￿
50
￿
mune donorTcellsis required
for detection of a host-derived
" Fbst
￿
LCMVspecific CTL response.
0
Donor
￿
Spleen and LN cells harvested
from cured carrier mice 61 d
after transfer of immune Thy-
1.1 cells were tested for their
ability to make an LCMV
specific CTL response. Before
in vivo stimulation with virus,
the indicated T cell popula-
tion(s) were depleted as de-
scribedin MaterialsandMeth-
ods. Percent specific killing at
an E/T ratio of 50:1 is shown.
had been depleted by in vivo treatment ofcured carrier mice with an mAb against
Thy-1.1 (19E1.2) before testing the host CTL response (21). In the results presented
in this paper, as shown in Fig. 1 and Table I, stimulation of cured carrier lympho-
cytes containing both donor and host T cells resulted in the generation ofCTL re-
sponses mediated predominantlyby donorT cells. Thesefindings suggestedthedom-
inance ofthe donor CTL response over the generation ofhost CTL activity. This
hypothesis was tested by the following experiment. Spleen and LN cells from cured
carriermice were pooled and then divided into four groups containing equalnumbers
ofcells. From one group, donor T cells were depleted, from one, host T cells, from
one, both host and donor T cells, and one group was mock treated (i.e., no cells
depleted). These four cell populations were then tested for their ability to generate
an LCMVspecific CTL response and to determine ifit is mediated by host ordonor
T cells. As shown in Fig. 3, a host (Thy-1.2)-derived LCMVspecific CTL response
was observed only in the donor T cell-depleted group. When both host and donor
T cells were present ("no depletion" group) the donor (Thy-1.1) CTL response was
dominant over the potential CTL response ofthe cured carrier host. This experi-
ment has been repeated two additional times with similar results (data not shown).
Discussion
This studyprovides direct evidence that virus-specific CTL can persist indefinitely
in vivo. This was accomplished by transferring Thy-1.1 Tcells into Thy-1.2 recipient
mice to specifically identify the donor T cell population and to characterize its anti-
genic specificity and function by using a virus-specific CTL assay. The transferred
LCMVspecific CTL persist in the recipient mice in small numbers and comprise
only a minor fraction ofthe total Tcells. Buton exposure to virusthesecells proliferate
in vivo to become the predominant cell population. These CD8+ T cells can be re-
covered up to ayear post-transferand still retain antigenic specificity and biological
function. TheykillLCMVinfected cells invitro and caneliminate virus upontransfer
into a second infected host. These results strongly suggest that virus-specific CTL
can persist for the life span of the host as memory cells.
In several instances natural infections, such as with measles virus, varicella, etc.,
andalsovaccinations with certain viruses, result inlong-lived T cellimmunity (23-25).
However, it is not clear if this is due to persistence of the initially primed T cellsJAMIESON AND AHMED
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and their progeny, or due to subsequent re-exposure to virus and the priming of
new (virgin) Tcells. Byadoptively transferringmarked (Thy-1 .1) mature T cells from
LCMVimmune mice into Thy-1.2 recipients, we have unequivocally shown that
primed virus-specific CTL and/or their progeny can indeed persist for a long and
indefinite period oftime. Thus, our results show that priming ofnew Tcells is not
necessary for maintaining long-term T cell immunity.
Inour experimentswe have examined thelongevityofvirus-specific CTL in cured
carrier mice, which at the time ofadoptivetransfercontained vastamounts ofvirus.
With the exception ofthe kidney, no viral antigen was detectable in the tissues of
thecured carriermiceat thetime donorTcellswere recovered. However, we cannot
rule out the possibility that the presence of minute amounts of viral antigen not
detectable by conventional assays, or virus within the kidney, provides continuous
antigenic stimulation to the donor T cells causing proliferation and maintenance
ofthis T cell population. It willbe ofinterest to determine iftheselong-lived LCMV-
specific CTLrequire antigen fortheir persistence. Arecent studyexamininghapten-
specific antibody responses has shown that B cell memory is short lived in the ab-
sence ofantigen (26). Experiments are currently in progress to investigate the life
span of virus-specific CTL in an antigen "free" environment.
Our study also provides direct evidence for the in vivo proliferation ofCD8+ T
cells during the induction of a CTL response. This is in contrast to the accepted
view ofcytotoxic T cell development, in which proliferation is thought to occur pri-
marily within the CD4+ T cell population with CD8+ T cells undergoing only
limited expansion (27). Several months after adoptive transfer, the donor CD8+ T
cells represented only a minor population (2.0-3.0% ofthe total spleen and LN cells)
ofthe freshly isolated resting lymphocytes from cured carrier mice. However, after
in vivo stimulation with virus, these cells expanded at least 5-10-fold in number to
become the predominant T cell population (27.4-52.0% ofthe total cells). In addi-
tion, the virus-specific CTL activity resided almost exclusively within this subset
ofcells (i.e., Thy-1.1+ CD8+ cells). Taken together, these results suggest that memory
CTL are present in small numbers in a "resting"stageand are capable ofexpansion
after exposure to viral antigen.
Our data also suggest that these long-lived CD8+ CTL are not dependent on help
from CD4+ T cells, since depletion of CD4+ T cells had minimal or no effect on
the biological properties (proliferation, CTL response, viral clearance) ofthe donor
CD8+ T cells. These results extend our previous finding that the primary CTL re-
sponse against LCMV does not require CD4+ T cells (28). Thus, it appears that
both the primary and memory LCMVspecific CTL responses can function in the
absence ofCD4' Tcells. It is possible that these long-lived CD8+ CTL are auto-
crine in nature and capable of producing the lymphokines necessary for their own
growth and activation. Alternatively, in the absence ofCD4+ T cells, help may be
provided by CD8+ helper cells within the donor and/or host T cell population. The
existence ofCD8' Th cells and the ability ofCD8+ T cells to produce IL-2 has been
shown in several systems (29-31).
Virus-specific CTL unresponsiveness is a hallmark of the LCMV carrier state
(6, 21, 22, 32, 33). In this report, we have again demonstrated that mice cured of
congenitally acquired chronic LCMV infection can generate a host-derived virus-
specific CTL response. This confirms our recent finding that mice previously in-2002
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fected byand unresponsive tothe virus canbecome immunocompetent and are then
protected against reinfection (21). The present study also extends the earlier finding
by showing that despite the ability ofthecured carrier host to generate a competent
LCMVspecific CTL response, donor-derived T cells mustbe removed before stim-
ulation ofcured carrier lymphocytes before a significant host CTL response can be
detected. This clearly demonstrates the dominance of the long-lived donor T cells
over the host response. This finding could be explained as the dominance of a sec-
ondary (donor) vs. a primary (host) response. A differential requirement by pri-
mary and secondary populations for lymphokines and antigens has been described
forMLCs (34). Primaryhost T cells mayhave more stringent requirements forlym-
phokines or antigenic stimulation than the secondary donor T cell population. In
addition, donor CTL precursors (CTLp) may exist in higher numbers than host
CTLp. Thus, the higher precursor frequencies and/or differential lymphokine re-
quirements would allowthe donor cellsto proliferate and respondmore rapidly than
the host, therefore, competing more successfully for antigen and growth factors re-
quired to activate the host CTLp. This would allow the donor population to effec-
tively dealwith thevirusbefore thehost cellswere extensively exposed and stimulated.
Tcell immunity is crucial indefense against viral, parasitic, and intracellularbac-
terial infections, and also in surveillance oftumors (35-37). Failure ofT cell immu-
nity often leads tochronic infections. Our results showingthat antigen-specificCTL
can persist indefinitely and retain the ability to mediate viral clearance has implica-
tions towards understandingthe immunological mechanisms effective in controlling
chronic infections and tumors. It is conceivable that one of the limiting factors in
the successful resolution ofcertain chronicinfections aretheselong-lived T cellscapable
ofpersisting andmediating clearance formonthsor even years. Strategies to restore
and/or increase the function and numbers of such T cells may be effective in the
treatment of chronic infections.
Immunological memoryis oneofthe most fascinating butleastunderstood aspects
of the immune system . Amajor obstacle in studying T cell memory has been the
difficulty in obtaining "pure" populations ofin vivo generated and selected memory
cells. The system we have developed may allow us to overcome this problem. Based
on our results, it is highly likely that the majority of Thy-1.1+ CD8+ T cells that
persist in cured carrier mice (Thy-1.2) are LCMV specific. Thus, it is possible to
obtain a highly enriched population of in vivo selected memory CTL and to ex-
amine their biological and physical characteristics. This should allow us to address
some fundamental questions about memory T cells.
Summary
This study documentsthatvirus-specific CTL can persist indefinitely in vivo. This
was accomplished by transferring Thy-1.1 T cells into Thy-1.2 recipient mice to
specifically identify the donor T cell population and to characterize its antigenic
specificity and function by using a virus-specific CTL assay. Thy-1.1 * T cells from
mice previously immunized with lymphocytic choriomeningitis virus (LCMV) were
transferred into Thy-1.2 mice persistently infected with LCMV. The transferred
LCMVspecific CTL (Thy-1.1+ CD8+) eliminate virus from the chronically infected
carriers and persist in the recipient mice in small numbers, comprisingonlya minor
fraction of the total T cells. Upon re-exposure to virus, these long-lived "resting"JAMIESON AND AHMED
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CD8' T cells proliferate in vivo to become the predominant cell population. These
donor CD8+ T cells can be recovered up to a year post-transfer and still retain an-
tigenic specificity and biological function. They kill LCMV infected H-2-matched
cells in vitro and can eliminate virus upon transfer into a second infected host. In
addition, these long-lived CD8' T cells appear not to be dependent on help from
CD4' T cells, since depletion of CD4+ T cells has minimal or no effect on their
biological properties (proliferation, CTL response, viral clearance). These donor CTL
also exhibit an immunodominance over the host-derived LCMVspecific CTL re-
sponse. When both host and donor T cells are present, the donor CTL response
is dominant over the potential CTL response of the cured carrier host. Taken to-
gether, these results suggest that virus-specific CTL can persist for the life span of
the host as memory cells.
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